StreetAlpha
Editas Medicine, Inc. · SEC Form 4

EDIT Insider Trading

From SEC Form 429 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Editas Medicine, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $177K sold.

← EDIT stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$177K16 sales · 3 insiders
Net−$177Kbought minus sold
Planned sales100%of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
2025-12: sold $15KDecJanFeb2026-03: sold $13KMarAprMay2026-06: sold $45KJun2026-07: sold $13KJul2026-08: sold $2KAug2026-09: sold $19KSepOct2026-11: sold $70KNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when EDIT insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an EDIT officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every EDIT insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Nov 11, 2026Linda BurklyEvp, Chief Scientific OfficerSale plan7,814$2.42$19K70,379Nov 13Form 4
Nov 11, 2026Gilmore Neil O'NeillCEOSale plan21,164$2.42$51K265,592Nov 13Form 4
Sep 3, 2026Gilmore Neil O'NeillCEOSale plan5,124$3.04$16K243,189Sep 4Form 4
Sep 3, 2026Linda BurklyEvp, Chief Scientific OfficerSale plan709$3.04$2K61,660Sep 4Form 4
Sep 3, 2026Amy ParisonSvp, CFOSale plan453$3.04$1K13,839Sep 4Form 4
Aug 3, 2026Amy ParisonSvp, CFOSale plan678$2.58$2K14,292Aug 5Form 4
Jul 28, 2026Linda BurklyEvp, Chief Scientific OfficerSale plan4,928$2.67$13K62,369Jul 29Form 4
Jun 3, 2026Linda BurklyEvp, Chief Scientific OfficerSale plan731$2.70$2K67,297Jun 5Form 4
Jun 3, 2026Gilmore Neil O'NeillCEOSale plan15,380$2.70$42K248,313Jun 5Form 4
Jun 3, 2026Amy ParisonSvp, CFOSale plan464$2.70$1K14,970Jun 5Form 4
Mar 3, 2026Linda BurklyEvp, Chief Scientific OfficerSale plan749$2.02$2K68,028Mar 4Form 4
Mar 3, 2026Amy ParisonSvp, CFOSale plan474$2.02$95715,434Mar 4Form 4
Mar 3, 2026Gilmore Neil O'NeillCEOSale plan5,394$2.02$11K263,693Mar 4Form 4
Dec 3, 2025Amy ParisonSvp, CFOSale plan461$2.15$99115,908Dec 4Form 4
Dec 3, 2025Gilmore Neil O'NeillCEOSale plan5,603$2.15$12K269,087Dec 4Form 4
🔒 14 more trades. Create a free account or sign in to see them all.

EDIT insider trading FAQ

Are EDIT insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of EDIT on the open market in 0 trades, and 3 sold $177K in 16 trades, 100% of that under pre-arranged trading plans.

When did an EDIT insider last buy shares?

There has been no open market insider purchase of EDIT in the last two years.

When did an EDIT insider last sell shares?

Linda Burkly (Evp, Chief Scientific Officer) sold 7,814 shares for $19K on Nov 11, 2026, under a pre-arranged trading plan.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice